

# Large Volume Parenteral (LVP) Market Growth Driven by Rising Hospital Demand & Expanding IV Therapy Applications | DataM

Large Volume Parenteral (LVP) Market to 2035: DataM Intelligence Projects Growth Driven by Chronic Disease Burden, Hospital Demand, and Expanding Home Infusion

NEW YORK, NY, UNITED STATES, September 12, 2025 /EINPresswire.com/ -- The global Large



Large Volume Parenteral support hydration, oncology, and antibiotics. U.S. leads with home infusion, Japan with aging care, and Europe with surgical demand."

DataM Intelligence Lead
Analyst

Volume Parenteral (LVP) Market is projected to grow from USD 12.5 billion in 2024 to USD 21.0 billion by 2035, at a CAGR of 5.0% over the forecast period (2025–2035). Expansion is fueled by rising hospital admissions, chronic disease prevalence, and the adoption of home-based infusion therapies. According to DataM Intelligence, the United States will remain the largest market, while Europe follows closely, and Japan demonstrates steady demand linked to aging populations and oncology care.

LVPs are fundamental for hospital care, including fluid replacement, parenteral nutrition, medication dilution, and

single-dose vaccine delivery. Rising demand is fueled by increased acceptance of single-dose vaccines, a preference for rapid drug administration, a growing aging population with chronic illnesses, and improved healthcare delivery in both developed and developing regions.

Headline Numbers (Global, U.S. & Japan)

- Global: USD 12.5B (2024) ☐ USD 21.0B (2035); CAGR 5.0%
- Japan: USD 1.5B (2024) 

  USD 2.1B (2035); CAGR 3.2%

Download Sample PDF (Get Higher Priority for Corporate Email ID) @ <a href="https://www.datamintelligence.com/download-sample/large-volume-parenteral-market">https://www.datamintelligence.com/download-sample/large-volume-parenteral-market</a>

**Market Drivers** 

- Chronic disease burden: Diabetes, cancer, and renal disease are increasing IV therapy use.
- Hospital & surgical growth: Higher surgical volumes globally sustaining infusion needs.
- Home infusion expansion: Rising demand for parenterals in ambulatory and home care settings.
- Regulatory & generic push: Supportive policies in Europe and Asia driving affordable access.

### Segment Insights

- By Volume: The 250–500 mL segment leads, commonly used for standard IV hydration and parenteral administration.
- By Application: Nutritious injections (e.g., vitamin and mineral formulations) and fluid balance injections are growth drivers, especially for elderly and post-surgical patients.
- By Packaging: LVPs are offered in both bottles and bags, with flexible bags gaining popularity due to ease of handling and reduced risk of contamination.



Large Volume Parenteral (LVP) Market | DataM Intelligence

## Competitive Landscape

Leading companies include B. Braun Melsungen AG, Baxter Healthcare, Fresenius Kabi, Pfizer, Emcure, Otsuka, Beximco Pharma, Ozon Pharmaceuticals, and China Resources Pharmaceuticals. Product launches, regulatory approvals (e.g., advanced multi-chamber nutrition bags), and high-protein/low-dextrose formulations (such as Baxter's Clinimix E) are shaping competitive differentiation.

### **Recent Developments**

- U.S.: Baxter expanded IV solution production under a new FDA-compliant sterile line.
- Japan: Otsuka Holdings announced a partnership with hospitals to expand oncology-focused LVP therapies.
- Europe: Fresenius Kabi opened a new IV fluid plant in Eastern Europe to meet generic demand.
- Global: B. Braun and ICU Medical announced supply agreements with hospital chains to secure long-term LVP contracts.

# Competitive & Regional Insights

• United States: Dominated by Baxter International, ICU Medical, Pfizer.

- Japan: Key players include Otsuka Holdings, Terumo, JW Pharmaceutical.
- Europe: Led by Fresenius Kabi, B. Braun, Grifols.
- Global trend: Increasing focus on home infusion systems, supply chain resilience, and sterile production compliance.

Outlook to 2035 (DataM Intelligence)

- Market to exceed USD 21B by 2035, with U.S. and Europe driving demand.
- Therapy mix: Oncology, renal care, and electrolyte solutions expected to grow fastest.
- Growth sensitivity: Linked to hospital capacity, chronic disease incidence, and regulatory reforms.

Looking for in-depth insights? Grab the full report: <a href="https://www.datamintelligence.com/buy-now-page?report=large-volume-parenteral-market">https://www.datamintelligence.com/buy-now-page?report=large-volume-parenteral-market</a>

**DataM Opinion & Analyst Recommendations** 

- Opinion: LVPs will remain mission-critical in global healthcare, but supply chain resilience and sterile compliance will be decisive factors in competitive positioning.
- For manufacturers:
- 1. Expand sterile IV capacity with automation,
- 2. Diversify sourcing to mitigate raw material risks,
- 3. Invest in home infusion-compatible packaging.
- For healthcare providers:
- 1. Partner with suppliers offering secure long-term contracts,
- 2. Adopt home infusion programs to reduce hospital burden.
- For policymakers:
- 1. Incentivize generic IV production,
- 2. Ensure redundancy in supply chains for critical therapies.

Regional Comparison Chart

Large Volume Parenteral (LVP) Market (2024–2035): Global vs. U.S. vs. Japan

Country-Level Snapshot

Region Market Size 2024 (USD B) Market Size 2035 (USD B) CAGR (2025–2035) Top Players Consumer Drivers

United States 3.8 6.9 5.2% Baxter International, ICU Medical, Pfizer Chronic disease management, hospital expansions, home infusion

Japan 1.5 2.1 3.2% Otsuka Holdings, Terumo, JW Pharmaceutical Aging population, oncology support, government healthcare programs

Europe 4.0 7.3 5.1% Fresenius Kabi, B. Braun, Grifols High surgical volumes, regulatory push for generics, hospital demand

Key Questions Answered in the Report

Q: Which regions lead the market growth?

A: The U.S. remains the largest market, Europe grows steadily with high surgical volumes, and Japan sustains moderate growth from its aging population.

Q: What is the impact of chronic disease and healthcare infrastructure?

A: Chronic illness and hospital expansions are the primary demand drivers, while home infusion adds new growth channels.

Q: Who are the top providers?

A: Leaders include Baxter International, Fresenius Kabi, B. Braun, Otsuka Holdings, Pfizer, and ICU Medical.

Methodology & Sourcing

Forecasts are based on DataM Intelligence's "Global Large Volume Parenteral (LVP) Market (2025–2035)" report. Estimates validated with company announcements, regulatory filings, and hospital demand trends (Q3 2025).

Unlock 360° Market Intelligence with DataM Subscription Services: <a href="https://www.datamintelligence.com/reports-subscription">https://www.datamintelligence.com/reports-subscription</a>

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights-all in one place.

Competitive Landscape
Sustainability Impact Analysis
KOL / Stakeholder Insights
Unmet Needs & Positioning, Pricing & Market Access Snapshots
Market Volatility & Emerging Risks Analysis
Quarterly Industry Report Updated
Live Market & Pricing Trends

Consumer Behavior & Demand Analysis

Have a look at our Subscription Dashboard: <a href="https://www.youtube.com/watch?v=x5oEiqEqTWg">https://www.youtube.com/watch?v=x5oEiqEqTWg</a>

More Reports:

<u>Smart Home Cameras Market</u> is expected to grow at a high CAGR of 5.7% during the forecasting period (2023-2030).

<u>Vegetable Puree market</u> to grow at a high CAGR during the forecast period 2024- 2031.

Sai Kumar
DataM Intelligence 4market Research LLP
+1 877-441-4866
sai.k@datamintelligence.com
Visit us on social media:
LinkedIn
X

- -

This press release can be viewed online at: https://www.einpresswire.com/article/848489830

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.